Merry Christmas and Happy New Year from Fusion!

Fusion Antibodies would like to wish everyone a Merry Christmas and a Happy New year. Instead of sending out Christmas cards this year Fusion Antibodies have made a donation to Cancer Focus NI. Cancer focus is a fantastic Northern Irish charity which helps local people affected by cancer. Fusion Antibodies are proud to support this charity and thank you for allowing us to make this donation in lieu of sending Christmas cards this year. 2013 has been a great year for Fusion with many great relationships formed with some great people around the world. Here’s to 2014, continued development of our Antibody Engineering platforms, stronger relationships with our clients and a prosperous year for everyone! Cheers.

Invest NI has offered the company R&D support of £22,704 with an additional £46,600 offered to support a broad range of market development activities.

Fusion Antibodies Ltd is helping to turn leading-edge research into novel drugs for the treatment of cancer and other chronic conditions with support from Invest Northern Ireland. With investment support form InvestNI, Fusion Antibodies have developed new technologies to support researchers develop drugs for the clinic. More details can be found on our most recent press release:

http://uk.prweb.com/releases/FusionAntibodies/InvestNI/prweb11361741.htm

Fusion antibodies CTO Dr Richard Buick has pledged to raise awareness for men’s health issues and will grow a moustache throughout November.

Fusion Antibodies Ltd has today announced a donation to support the worldwide Movember foundation. Fusion antibodies CTO Dr Richard Buick has pledged to raise awareness for men’s health issues and will grow a moustache throughout November. Movember started in Melbourne Australia in 2003 with just 30 people and has now grown to over a million participants in over 21 countries worldwide. The campaign hopes to “change the face of men’s health” by prompting conversation about serious issues including mental health, prostate and testicular cancer.

We would encourage anyone who reads this to make a donation to the Movember foundation.

You can also read our full press release here.

Fusion Antibodies CDRx platform has rapidly developed high quality humanized antibodies for Exeter based company Isca Diagnostics.

The EU funded project will allow ISCA Diagnostics to provide the healthcare profession with easy access to rapid and accurate diagnostic tests for human mycoses.

More details of the collaboration can be found on our recent press release on the Press Release at

http://uk.prweb.com/releases/FusionAntibodies/AntibodyHumanization/prweb11236850.htm

Fusion Antibodies have developed a next generation computer platform for rapid, high quality generation of humanized antibodies.

The CDRx platform modernizes the traditional CDR grafting technique by in silico grafting parental CDR’s into mature human antibody frameworks. The CDRx platform screens a database of over 100,000 antibody sequences with bespoke algorithms and, by multiple analytical techniques, defines a panel of human donor frameworks. Once generated, the full length humanized antibodies can be further refined (or germlined) to be even more “human”.

The CDRx platform has went from strength to strength over the past 12 months and thanks to our two-fold affinity guarantee we have seen a 100% success rate. Moreover, we have had the privilege to work with some fantastic clients and humanize what promises to be crucially important drugs in their respective fields. Following recent announcement of the CALY-002 humanization with Calypso Biotech for Celiac Disease, Fusion Antibodies plan to soon announce a new collaboration for humanization of a anti-fungal antibody. This proves the versatility of our platform and the range of exciting targets we can humanize in addition to those in the oncology field.


Fusion Antibodies CDRx platform allows rapid antibody humanization in as little as 12 weeks

The Fusion Antibodies Humanization CDRx platform allows us to do more than our competitors because we not only have no theoretical limit to the number of sequences we can analyse, but we can do complex analysis extremely fast. We can deliver a panel humanized sequences in as little as two weeks, with gene synthesis and transient expression of proof-of-concept material in as little as 12 weeks. We screen for t-cell epitopes, produce a chimeric control antibody in parallel and most importantly don’t charge any royalties. Our modular ordering system allows our clients to pick and choose the services they require allowing for maximum flexability.

The next 12 months looks set to be very exciting as we develop the platform further and see progression of our clients humanized antibodies through the clinic.

Andrew Glover, Business Development Executive

Our Fsn0503 poster will be displayed at this year’s International Conference on Molecular Targets and Cancer Therapeutics

Our poster for “Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.” Will be displayed at:

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

http://www.aacr.org/home/scientists/meetings–workshops/molecular-targets-and-cancer-therapeutics.aspx

October 19-23, 2013
Hynes Convention Center
Boston, MA, USA  Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors .

Session ID: Poster Session C

Session Title: Monoclonal Antibodies

Session Date and Time: Tuesday Oct 22, 2013 12:30 PM – 7:30

PMLocation: Exhibit Hall C-D

Permanent Abstract Number: C161